Xilio Therapeutics, Inc.

NASDAQ:XLO

0.99 (USD) • At close November 8, 2024
Bedrijfsnaam Xilio Therapeutics, Inc.
Symbool XLO
Munteenheid USD
Prijs 0.99
Beurswaarde 43,517,360
Dividendpercentage 0%
52-weken bereik 0.49 - 1.93
Industrie Biotechnology
Sector Healthcare
CEO Dr. Rene Russo BCPS, Pharm.D, Pharm.D.
Website https://www.xiliotx.com

An error occurred while fetching data.

Over Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a

Vergelijkbare Aandelen

Adverum Biotechnologies, Inc. logo

Adverum Biotechnologies, Inc.

ADVM

8 USD

Cytosorbents Corporation logo

Cytosorbents Corporation

CTSO

0.74 USD

Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc.

LUCD

1.04 USD

Tabula Rasa HealthCare, Inc. logo

Tabula Rasa HealthCare, Inc.

TRHC

10.5 USD

Alzamend Neuro, Inc. logo

Alzamend Neuro, Inc.

ALZN

1.49 USD

Capricor Therapeutics, Inc. logo

Capricor Therapeutics, Inc.

CAPR

19.7 USD

HOOKIPA Pharma Inc. logo

HOOKIPA Pharma Inc.

HOOK

3.76 USD

Puma Biotechnology, Inc. logo

Puma Biotechnology, Inc.

PBYI

2.88 USD

PAVmed Inc. logo

PAVmed Inc.

PAVM

1.11 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)